[Prevention of recurrent infection of the upper and lower airways. Multicenter, open study over three months]

In a multicenter open study involving 620 patients suffering from recurrent infections of the upper and lower respiratory tract aged between 12 and 89 years, the tolerability of an oral bacterial lysate was investigated. On the basis of the nature and frequency (1.9%) of adverse effects, and an analysis of the laboratory investigations over an observation period of three months, overall tolerability was adjudged to be excellent. The frequency and severity of infections was reduced. In 75% of the cases, both physician and patient considered the augmentation of the body's defense mechanisms by immunoactivation to have been of benefit. The favourable risk-to-benefit ratio results in a high level of acceptance of immunotherapy, and 96% of the patients completed the study as planned.